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Abstract Clozapine (CLO), an atypical antipsychotic
used in the clinic for treatment of schizophrenia, has a
well-known efficacy, but its general use in clinical prac-
tice is limited because of the risk of serious side effects.
Therefore, in the present work, we focused on the en-
capsulation of CLO into polymeric polycaprolactone
nanoparticles (PCL NPs) and studies of interactions of
this nanoformulation with model cells. Two types of
clozapine PCL NPs (CLO-PCL NPs), pegylated and
non-pegylated, were obtained by nanoemulsion
templating method. The complex interactions of these
NPs with three model cell lines (HEK 293, human
embryonic kidney cell line; RAW 264.7, murine mac-
rophage cell line; hCMEC/D3, model of blood-brain
barrier, BBB) were studied. Cell viability, cellular up-
take of NPs, NO release, expression of pro-
inflammatory agents and transcytosis experiments were
performed. Pegylated CLO-PCL NPs showed better
results in the tests performed in the present study, in
comparison to non-pegylated ones: they are not toxic to
model cells; pegylated outer surface protected from their
fast uptake by macrophages; they were not immunogen-
ic; transcytosis experiments pointed to their ability to
cross a model BBB. The results obtained in the present
study indicate that pegylated CLO-PCL NPs are prom-
ising carrier for antipsychotic drugs directed to cross
BBB. The experiments were conducted using only
in vitro models but they provide valuable data in the
field of nanotechnology which can be used in novel
molecular pharmacology.
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Introduction
Over the past decades, nanomaterials attract most atten-
tion due to the possibility of their biomedical applica-
tions. Nanoparticles (NPs) can constitute useful tool for
selective transportation of lipophilic, poorly water-
soluble or evenwater-insoluble active compounds. Such
strategy allows to maintain the desired properties of the
drugs by protection from the unfavourable biological
environment (Anton et al. 2009; Maghraby et al. 2006;
Mainardes and Silva 2004). It is also known that, in
addition to influencing the cellular uptake, particle size
can also influence drug loading, drug release and the
stability of NPs (Mottaghitalab et al. 2015). Other im-
portant advantages of NPs are extending drug preva-
lence in the organism, decreasing its degradation ratio
and potential to modify the NPs structure, so they can
become specific and able to reach appropriate targets
(Muthupandian et al. 2018; Saravanan et al. 2014;
J Nanopart Res (2019) 21: 149
https://doi.org/10.1007/s11051-019-4587-1
S. Łukasiewicz (*) :A. Mikołajczyk :
M. Dziedzicka-Wasylewska
Department of Physical Biochemistry, Faculty of Biochemistry,
Biophysics and Biotechnology, Jagiellonian University, 7
Gronostajowa Street, 30-387 Krakow, Poland
e-mail: sylwia.lukasiewicz@uj.edu.pl
M. Szczęch :K. Szczepanowicz : P. Warszyński
Jerzy Haber Institute of Catalysis and Surface Chemistry PAS,
30-239 Krakow, Poland
Wilczewska et al. 2012; Khan et al. 2015). Many tech-
niques were described for modification of different sur-
faces to enable them to work as so-called surface cap-
sules (Zhukova and Skorb 2017). In this way
nanocarriers can be specifically developed to achieve
an “intelligent targeting” and controlled release. Devel-
opment of nanostrategies in controlled drug delivery
systems has been extensively reviewed (Ghadiri et al.
2017; Farokhi et al. 2016; Mottaghitalab et al. 2015;
Khan et al. 2012; Alibolandi et al. 2014, 2016). Various
types of nanoformulations have been described as po-
tential nanocarriers. However, polymeric NPs demon-
strate better reproducibility and stability profiles than
others (Abedini et al. 2018). The present study focuses
on biocompatible polymeric nanoparticles made of
polycaprolactone (PCL). PCL NPs are characterized
by a diameter lower than 100 nm and ability of passive
targeting and sustained drug release (Kim et al. 2015).
What is more, over the last few years, a significant
necessity emerged to evaluate PCL NPs possible phar-
maceutical applications in drug delivery systems, due to
their ability to transport variety of hydrophobic drugs
and relatively lower cost of production and more satis-
fying biocompatibility (Peng et al. 2015).
One of the crucial challenges in therapy is to deter-
mine how efficient PCLNPs can penetrate desired tissue
at therapeutically effective dose. Studies on the possible
use of PCL NPs loaded with cytostatic drug—
carboplatin for intranasal delivery have shown satisfy-
ing capability of permeation through nasal mucosa with-
out any damaging effect on the tissue. Furthermore, they
proved similar drug release rates in both in vivo and
in vitro studies against human glioblastoma cells LN229
(Lupi et al. 2014). Additionally, study on pegylated PCL
NPs with encapsulated neuroprotective compound
(NAP) has showed very promising intranasal adminis-
tration via clathrin-/caveolae-mediated endocytosis, as
well as biodistribution in the rat brain. Therefore, they
may serve as an opportunity for effective treatment of
neurodegenerative diseases such as Alzheimer’s disease
(Agrahari et al. 2016).
PCL NPs have also been tested for their possible use
in treatment of conditions beyond CNS. Studies dem-
onstrated that nanoparticles smaller than 100 nm were
absorbed easier by immune cells like macrophages or
dendritic cells in areas of inflammation. It provides an
opportunity to use encapsulated therapeutics in treat-
ment of diseases such as ulcerative colitis (UC) and
Crohn’s disease (CD) (Zhang et al. 2002).
Recently, polymeric NPs were tested as potential
nanoadjuvants in creating vaccines inducing prolonged
resistance (Alexis et al. 2008; Mathaes et al. 2014). PCL
NPs with encapsulated anatoxin tetanus toxoid (TT)
have been used to determine macrophage polarization
and antigen presentation mechanism by human
monocyte-derived macrophages. The results of the trial
showed that small NPs (range 61.2 nm) caused constant
and pro longed bo th humora l and ce l lu l a r
immunoresponse against TT. It may be a symptom that
this type of immunization—via long time of degradation
and high biocompatibility of PCL NPs—has a great
potential as single shot vaccines (Mathaes et al. 2014).
The nanostrategy is also very promising, especially
in case of neurodegenerative, neuropsychiatric and other
brain diseases where the delivery of active compound to
the desired brain regions remains still a big challenge.
The main reason of insufficient treatment of brain dis-
eases is the presence of blood-brain barrier (BBB).
Some nanostrategies developed to overcome the prob-
lem have been described (Ghadiri et al. 2017; Yeste et al.
2018). One of the brain diseases still without satisfactory
therapy is schizophrenia. It is a serious disorder of brain
and mind that affects ca. 1% of human population
(Stępnicki et al. 2018). Schizophrenia finds place within
10 diseases that cause the greatest social disability and it
generates enormous costs of therapy. It is an extremely
devastating, complex disease manifested by both behav-
ioural and cellular dysfunctions. The cause of schizo-
phrenia is still not fully elucidated; dysregulation of few
neurotransmission systems is taken into account, includ-
ing glutamatergic, as well as dopaminergic and seroto-
nergic systems (Ali et al. 2017). Various antipsychotic
drugs are available and used in the clinic, but it has been
widely demonstrated that between 20% to even 60% of
patients with schizophrenia do not respond sufficiently
to conventional treatments (Howes et al. 2017).
Clozapine (CLO, dibenzodiazepine) is a
multireceptorial atypical antipsychotic compound with
well-documented efficacy, also in the treatment-resistant
schizophrenia (Berardis et al. 2012). The precise mech-
anism of action of the drug is still unknown; however, its
therapeutic effects are probably mediated by dopami-
nergic and serotonergic activity (Meltzer and Huang
2008). Although CLO is well absorbed after oral admin-
istration, it undergoes extensive first-pass hepatic me-
tabolism, resulting in poor oral bioavailability (Kadam
et al. 2012; Manjunath and Venkateswarlu 2005). In
addition, its low plasma half-life points towards
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extensive metabolic clearance (Kadam et al. 2012). One
of the major limitations of treatment with CLO is inef-
ficient delivery of the drug to the appropriate part of the
brain.
Although CLO has well-known and documented
antipsychotic efficacy (it is effective in the treatment of
both positive and negative symptoms of schizophrenia
and has low extrapyramidal side effects (Essali et al.
2009; Warnez and Alessi-Severini 2014)), its clinical
use is diminished because of multitude of adverse ef-
fects arising from its long-term administration (i.e. ar-
rhythmias, weight gain, metabolic dysfunction linked to
diabetes, myocarditis, cardiomyopathy and, above all,
agranulocytosis (Warnez and Alessi-Severini 2014;
Berardis et al. 2018)). Although, FDA (Food and Drug
Administration) and the drug’s manufacturer have
strengthened warnings that a potentially fatal myocardi-
tis may occur when taking CLO (Berardis et al. 2012), it
still remains the drug of choice in treatment-resistant
schizophrenia (Remington et al. 2016). It has been dem-
onstrated that CLO is more effective than any other of
first-generation (FGA) or second-generation antipsy-
chotics (SGA) in the treatment of resistant schizophrenia
and it is also useful in other conditions (Siskind et al.
2016; De Berardis et al. 2013). It has been estimated that
almost two thirds of those patients who do not respond
adequately to treatment with FGAs or other SGAs may
respond adequately to treatment with CLO (Essali et al.
2009). Undoubtedly, it is a very effective drug in every-
day clinical practice and many patients who tolerate it
will experience remarkable relief of symptoms (Orsolini
et al. 2016). However, there are many patients who do
not tolerate this drug. Considering the above features of
CLO, it is not surprising that there is a need to find a
more efficient and safer route of administration of this
drug Therefore, the development of new form of CLO,
allowing its controlled release, which may improve its
therapeutic potential, is one of the most significant
topics for modern neuroscience. Recently, several dif-
ferent nanoformulations of CLO have been presented
(Moraes et al. 2016; Kirbay et al. 2017; Vieira et al.
2016; Panda et al. 2016; da Costa Güllich et al. 2015).
The findings show that various CLO nanoformulations
may lead to decrease of side effects suggesting that the
drug, when loaded to different nanocapsules, is able to
mitigate the harmful effects (da Costa Güllich et al.
2015).
In the present work, CLO was encapsulated into
polycaprolactone polymeric nanoparticles (CLO-PCL
NPs). Two types of CLO-PCL NPs (non-pegylated
and pegylated) were synthesized by nanoemulsion
templating method. Pegylation is well-documented
modification of outer surface of NPs which minimizes
the fast clearance of NPs from the blood and makes
particles invisible to the immune system. PEG is an
uncharged, hydrophilic polymer, whose extensive hy-
dration, high conformational flexibility and high chain
mobility account for a steric exclusion effect (Torchilin
and Trubetskoy 1995). The protein resistance of PEG-
based coatings depends on both the length of chains and
their density (Milton Harris and Chess 2003; Vermette
and Meagher 2003; Halperin 1999; Zhu et al. 2001).
Moreover, the interactions of obtained clozapine PCL
nanoparticles (CLO-PCL NPs) with various model cells
(HEK 293, RAW 264.7, hCMEC/D3) were studied. The
biocompatibility, immunomodulatory effects, uptake,
endocytosis pathways, phagocytic potential and
transcytosis were estimated.
Experimental section
Materials
CLO-PCL-NPs preparation
Clozapine was received from Tocris. Polycaprolactone
PCL (Mw ~ 10,000) and poly(ethylene glycol)-block-
poly(ε−caprolactone) methyl ether PCL-b-PEG (PCL
Mw ~ 13,000, PEGMw ~ 5000), poly(ethylene glycol),
TWEEN® 20 (sorbitan monolaurate) and Span® 20
(sorbitan monolaurate) were obtained from Sigma-Al-
drich. Toluene was purchased from Avantor Perfor-
mance Materials. Distilled water was from the Direct-
Q 5UV purification system from Millipore. All
chemicals were used as received without further
purification.
Materials for cell culture assays
Mouse murine macrophage cell line (RAW 264.7) was
obtained from Sigma-Aldrich. The immortalized human
cerebral microvascular endothelial cells, D3 clone
(hCMEC/D3) was kindly provided by Prof. Babette
Weksler (Cornell University, NY). Human embryonic
kidney 293 (HEK 293) cells were obtained from the
American Type Culture Collection. The cell culture
materials, including heat-inactivated foetal bovine
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serum (FBS), EDTA/Trypsin solution, endocytosis in-
hibitors (chlorpromazine, amiloride, filipin III), rat col-
lagen, TRI-Reagent, DMEM, MEM, F12 media and
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetra-
zolium bromide), were purchased from Sigma-Aldrich.
The cell culture EGM-2 media with all supplements
were from Lonza. Lactate dehydrogenase (LDH) Cyto-
toxicity Detection Kit was from Clontech Laboratories.
Vybrant Phagocytosis Kit, Griess Reagent Kit for Nitrite
Determination were from Molecular Probes (Thermo
Scientific). All molecular biology reagents, as well as
Luminaris HiGreen qPCR Master Mix, were obtained
from Thermo Scientific. Oligonucleotides were synthe-
sized by Genomed S.A.
Methods
CLO-PCL-NPs preparation
CLO loaded in polymeric nanocarriers were prepared
according to the method described previously (Szczęch
et al. 2017), by nanoemulsion templating method. Two
types of CLO polymeric nanocarriers were synthesized:
pegylated and non-pegylated. The nanoemulsion of tol-
uene containing CLO (0.6 mg/ml) mixture of polymers
PCL-b-PEG (0.13 mg/ml with PCL 2.88 mg/ml) or bare
PCL (3mg/ml), in water stabilized by TWEEN® 20 and
Span® 20 surfactants, was formed by the PIC technique
(phase inversion composition) at constant temperature.
Nanoemulsion was composed as follows: 20% (v/v) oil
phase, 5% (v/v) Tween20/Span20 (HLB = 13.5) and
75% (v/v) water. After preparation of nanoemulsion,
organic solvent (toluene) was removed by evaporation,
while surfactants were removed by dialysis. Fluores-
cently labelled NPs were prepared by encapsulation of
fluorescent dye (Coumarin-6) into formed NPs.
Coumarin-6 was dissolved in the oil phase at concen-
tration 0.5 mg/ml before the nanoemulsification
process.
CLO-PCL NPs characterization
The hydrodynamic size of prepared CLO-PCL NPs was
measured by the dynamic light scattering (DLS) tech-
nique using Zetasizer Nano ZS, Malvern Instruments.
The values were received as an average of at least three
subsequent measurements with 20 runs. The concentra-
tion of synthesized clozapine nanocarriers was
measured by nanoparticle tracking analysis (NTA) using
NS500 NanoSight Malvern Instruments. All measure-
ments were evaluated at 25 °C. To evaluate the stability
of the synthesized NPs, their hydrodynamic size was
monitored in time during storage in the preparation
buffer (water) as well as in cell culture media (DMEM
containing 10% FBS). All measurements were evaluat-
ed at 25 °C.
Cell culture
RAW 264.7 cells were grown in DMEM supplemented
with 1% L-glutamine, high glucose and 10% heat-
inactivated foetal bovine serum (FBS). HEK 293 cells
were grown in MEM supplemented with 1% L-
glutamine and 10% heat-inactivated FBS. The
hCMEC/D3 cell line was grown in EBM-2 (endothelial
cell basal medium) supplemented with components ob-
tained from the manufacturer (human epidermal growth
factor (hEGF), vascular endothelial growth factor
(VEGF), R3-insulin-like growth factor-1 (R3-IGF-1),
ascorbic acid, hydrocortisone, human fibroblast growth
factor-beta (hFGF-β) , heparin , gentamicin/
amphotericin-B (GA) and 10% FBS. To provide optimal
growth conditions, the hCMEC/D3 cells were seeded on
tissue culture plates, dishes or flasks coated with rat
collagen (final protein concentration 150 μg/ml). All
the cell lines were cultured at 37 °C in a humidified
incubator with a 5% CO2 atmosphere. The medium was
changed every 3–4 days. hCMEC/D3 cells were used at
passages 26–34. After hCMEC/D3 cell culture condi-
tions were established, the cell marker characteristic for
BBB cells was established as described previously [52].
Two days before the MTT, LDH and NO tests, cells
were seeded into the appropriate 96-well plates at a
density of 3 × 104 cells per well. For flow cytometry
and qPCR measurements cells were seeded into 6-well
plates at a density of 3 × 105 cells per well. Five days
before transcytosis experiments, the hCMEC/D3 cells
were seeded 13 × 103 cells per well into appropriate 96-
well plates (HTS FluoroBlokTM Multiwell Insert Sys-
tem) on collagen type I-coated Transwell membrane
permeable supports with 3 μm (96-well plate) or
48.5 × 103 cells in 24-well plates (Falcon Cell Culture
Inserts) on collagen type I-coated 1 μm (24-well plate)
pore size. Before Vybrant Phagocytosis test cells were
seeded in 96-well microplates—1 × 105 RAW 264.7
cells per well.
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Cell viability and cytotoxicity assays
MTT reduction test
MTT reduction test was performed to evaluate RAW
264.7 and HEK 293 cells viability. Different types of
CLO-PCL NPs, pegylated and non-pegylated were
added in variable doses to the fresh medium into each
well, respectively. Doses of ca. 16,500, 7000 and 3500
NPs per cell were used. Twenty-four hours cells were
incubated with the NPs, thenmediumwas aspirated, and
replaced with 50 μl of 0.5 mg/ml MTT (3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) resus-
pended in serum-free medium. After 4 h incubation at
37 °C in a 5% CO2 atmosphere, medium was removed
and 100 μl of DMSO was added to each well. After
10 min of incubation with shaking, the absorbance was
measured at 570 nm using a microplate reader (TECAN
Infinitive M200 Pro). Untreated cells incubated only
with fresh medium constituted a control. Six replicates
for each types and dose of CLO-PCL NPs were done.
Presented result reflect the effect obtained from 5 inde-
pendent experiments.
CellTiter-Blue® Cell Viability Assay The hCMEC/D3
cell viability was established using the CellTiter-Blue®
Cell Viability Assay. Various doses (ca. 16,500, 7000,
3500 NPs per cell) of obtained CLO-PCL NPs were
added into each well, respectively. Twenty-four hours
cells were treated with particles. Then, after medium
aspiration, the freshly prepared complete medium
(100 μl per well) supplemented with CellTiter-Blue
reagent (20 μl per well) was added to each well. The
fluorescence signal was acquired (TECAN Infinitive200
excitation wavelength 560 nm; emission wavelength
590 nm) after 3 h incubation at standard culture condi-
tion. Control experiments determine untreated cells. Six
replicates for each type of CLO-PCL NPs were mea-
sured. The final results reflect the average cell viability
acquired from 4 independent experiments.
LDH cytotoxicity detection kit
The LDH (lactate dehydrogenase) released into the cell
culture medium is correlated with cell membrane desta-
bilization and destruction and marks cytotoxicity of
tested nanomaterials. The assay was conducted in
RAW 264.7 and HEK 293 cells after 4 h of incubation
with synthesized CLO-PCL NPs (doses were analogous
to the MTT assay). 96-well plates were centrifuged at
250g for 7 min. Then, 50 μl of culture medium was
added to 50 μl of the reaction mixture and incubated for
30 min in the dark at room temperature. The colorimet-
ric reaction products were monitored by absorbance
measurements at 490 nmwavelength (with the reference
wavelength at 610 nm) (TECAN Infinitive200). Nega-
tive control was determined for untreated cells (sponta-
neous LDH release). Positive control—maximum LDH
release level—was measured after addition of Triton X-
100 (causing cell death) to appropriate wells. Six repli-
cates for each types and dose of CLO-PCL NPs were
done. Presented result reflects the effect obtained from 4
independent experiments.
Flow cytometry experiments
Flow cytometry was adopted to the quantitative cellular
uptake measurements. The experiments were performed
for different types of obtained CLO-PCL NPs in various
cell lines: RAW 264.7 and hCMEC/D3. Cells were
cultured in the standard condition and before the exper-
iment, CLO-PCL NPs (fluorescently labelled with cou-
marin) were added to the fresh full medium (at various
doses ca. 100, 500, 1000, 2000, 3500, 5000 NPs per
cell, respectively) and incubated for 4 h at 37 °C, in a 5%
CO2. Non-absorbed NPs were removed during rigorous
washing (4 times using cold PBS, phosphate buffer
saline, pH 7.4). For the measurements, cells were
suspended in 300 μl of cold PBS. To establish which
endocytosis pathway is engaged in the process, cells
were pre-incubated (1 h) under standard culture condi-
tion with specific endocytosis inhibitors (chlorproma-
zine (CPZ 8 μg/ml), filipin III (1 μg/ml) and amiloride
(50 μM), respectively). The uptake experiments were
done using BD FACSCalibur flow cytometer and
CellQuestPro software. Ten thousand events were ac-
quired for each sample. Treatment of the cells with
0.015 M NaCl as well as non-fluorescent CLO-PCL
NPs determines the background (autofluorescence).
Two replicates for each CLO-PCL NPs were measured.
The obtained results represent the average of 4 indepen-
dent experiments.
No determination test
For determination of NO released by RAW 264.7 cells
as a result of interaction with CLO-PCL NPs, Griess
Reagent Kit for Nitrite Determination was used,
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according to the manufacturer’s protocol. Cells were
incubated for 4 h under standard culture conditions in
the presence of various types and doses of CLO-PCL
NPs (ca. 16,500, 7000, 3500 NPs per cell). After incu-
bation, 75 μl of supernatant from each well was mixed
with 10 μl of Griess Reagent and incubated for 30 min
in dark at room temperature. The reference sample was
prepared by mixing 10 μl of Griess Reagent and 140 μl
of deionized water. The NO release was detected by
measurement of absorbance at 548 nm using a micro-
plate reader (TECAN Infinitive200). Untreated cells
incubated with fresh medium constituted a control. Six
replicates for each CLO-PCL NPs dose were measured.
The final results reflect the average acquired from 3
independent experiments.
Vybrant phagocytosis assay
A phagocytosis assay was conducted according to the
manufacturer’s protocol. Obtained CLO-PCL NPs were
added to the cells (doses of ca. 7000, 3500 NPs per cell)
for 2 h in standard culture conditions. Then, medium
was removed and the cells were incubated for 2 h at
37 °C with fluorescein-labelled E. coli particles (HBSS
buffer). Finally, the bacterial particles were aspirated
and Trypan Blue (which quenched fluorescence
resulting from non-internalized E. coli) was added to
each well. Non-NPs treated cells were used as a positive
and free medium as a negative control. The fluorescence
measurements were performed using 488 nm excitation,
5 2 0 nm em i s s i o n wav e l e n g t h s ( TECAN
Infinitive200Pro). For each type of used NPs, 5 repli-
cates were conducted. Final results consist the average
from 3 independent experiments.
qPCR (quantitative real-time PCR) experiments
The various doses (ca. 500, 2000, 3500 NPs per cell) of
CLO-PCL NPs were incubated with RAW 264.7 cells at
37 °C in a 5% CO2 incubator for 4 h in the complete
fresh medium. Total RNA was isolated using Tri-
Reagent and phenol-chloroform extraction. One micro-
gram of total RNAwas reverse transcribed to cDNA and
used in the qPCR reaction with the specific primers
(Table 1) and Luminaris HiGreen qPCR Master Mix
(Eco™ Real-Time PCR System-Illumina). GAPDH
was reference gene, untreated cells were the reference
sample.
CLO-PCL-NPs transcytosis experiments
Fresh culture medium containing coumarin-labelled
CLO-PCL NPs in dose ca. 5000, NPs per cell were
prepared and used in transcytosis experiments. Briefly,
the medium was added to apical side of hCMEC/D3
monolayer. The basolateral part of chamber comprise
the fresh medium without NPs. The signal comes from
the coumarin was acquired from the basolateral part of
the plate every hour. In case of transwell inserts with
1 μm pore size (24-well plate), the basolateral medium
(100 μl) was received at each time point, transferred to a
96-well plate and measured. Fluorescence was mea-
sured at 485 nm excitation and 520 nm emission wave-
length (TECAN Infinitive200). Additionally two types
of control experiments—where signal was acquired
from wells with non-NPs treated cells as well as from
empty (with no cells) transwells—were performed. Two
replicates for each type of NPs were done. Final results
reflect the effect from 4 independent experiments.
Statistical analysis
Final data are presented as the mean ± standard error
(SEM). The statistical significance was determined
using the parametric Student’s t test and non-
parametric Mann-Whitney U test; *p < 0.05,
**p < 0.01, ***p < 0.001.
Results and discussion
Improved pharmacotherapy for schizophrenia still re-
mains a key challenge for molecular pharmacology.
Table 1 Specific primers used in qPCR reactions
Primer Sequence
GAPDH-for TCAACGGCACAGTCAAGG
GAPDH-rev ACTCCACGACATACTCAGC
IĸBαFOR CTTGGTGACTTTGGGTGCTGAT
IĸBαREV GCGAAACCAGGTCAGGATTC
iNOFOR TCCTACACCACACCAAAC
iNOREV CTCCAATCTCTGCCTATCC
IL-6FOR TTCTCTGGGAAATCGTGGAAA
IL-6REV TCAGAATTGCCATTGCACAAC
TNF-αFOR CCCTCACACTCAGATCATCTTCT
TNF-αREV GCTACGACGTGGGCTACAG
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Finding a new active compound which will be effective
in the clinic and at the same time will not cause serious
side effects is difficult to achieve. Therefore, we focused
on the obtaining novel nanoformulation of well-known
antipsychotic compound such as clozapine (CLO). The
new strategy may be more safe (not generating serious
side effects) and would contribute to improvement of
therapeutic potential of the drug.
The synthesized CLO-PCL NPs were characterized
by measurements of their size (i.e. hydrodynamic diam-
eter), concentration and zeta potential as summarized in
Table 2. For the synthesis of pegylated NPs, we used the
mixture of two polymers: PCL and its copolymer PCL-
b-PEG with the PEG (MW 5000). These components,
compared to the non-pegylated ones where we used the
only PCL, were added together to the oil phase for the
formation of polymeric cores. The differences between
the mean size of CLO-PCL-PEG and CLO-PCL NPs
may be caused by different amounts of PCL/PCL-b-
PEG and single PCL dissolved in the nanoemulsion
droplets. That is why after the evaporation of an organic
solvent, we obtained differences in the mean size of
particles due to the method of their preparation. We
could observe the size increasing if we will modify the
PCL NPs by pegylation after their synthesis. However,
we performed two different syntheses. The PDI index
for both type of NPs below 0.3 which confirm mono-
disperse character of synthesized nanoparticles. The
stability of obtained NPs in cell cultured media contain-
ing 10% FBS was evaluated. The nanomaterials were
stable in mentioned above condition since they retained
their size without significant changes for at least 48 h
[51]. Long-term stability tests were performed in prep-
aration buffer (water), and up to 6 months, we did not
observe significant changes in the hydrodynamic size
and zeta potential of tested nanoparticles.
Cytotoxicity of CLO-PCL NPs
Biomedical applications of CLO-PCL NPs require wide
investigation which enable the description of the inter-
action between particles and model cells. Nanomaterial
toxicity is a major factor in determining its applicability
for drug delivery. Therefore, the cytotoxicity of prepared
CLO-PCL NPs was evaluated. MTT as well as LDH
assays were adopted to the study. The results are similar
for both investigated cell lines, RAW 264.7 and HEK
293, and indicate that viability of the cells strongly
depends on pegylation of CLO-PCL NPs. Estimated
level of cells viability for pegylated CLO-PCL NPs is
near 100%. The highest undesired effect was observed
for the highest dose of unmodified CLO-PCL NPs
(Fig. 1a, b).
The most probably, this effect might be caused by
free CLO which may have spontaneously released from
non-PEG covered particles. This interpretation is in a
way confirmed by the results obtained for free PCL NPs
(data not shown) since we did not see any difference in
cells viability (ca. 80–90%) between pegylated and non-
pegylated carriers. Cytotoxicity of nanomaterials mainly
depends on the interaction between NPs and cell mem-
brane and is correlated with the charge, shape, size,
surface area, flexibility, surface chemical properties
and amphipatic character of NPs (Nel et al. 2006;
Hong et al. 2006; Lee and Larson 2008; Leroueil et al.
2008). Charged NPs interact with cell membrane mainly
in the electrostatic way (Nel et al. 2006; Hong et al.
2006). The literature data connect the observed toxic
effect of nanomaterials with increased adsorption of
NPs (especially positively charged) on the cell mem-
brane, decreasing of lipid density and, eventually, the
plasma membrane disruptions (Verma and Stellacci
2010). Therefore, LDH release test, in which membrane
integrity is assessed by monitoring the efflux of cyto-
plasmic lactate dehydrogenase into the cell culture me-
dium, was performed following incubation of cells with
obtained CLO-PCL NPs. Promising results (Fig. 1c, d)
were obtained since we did not observe LDH release
above the level characteristic for control cells. The re-
sults were similar for both cell lines (RAW 264.7 and
HEK 293). Comparison of cytotoxic effects generated
by various types of PCL NPs synthesized by others
indicates the safe profile of the nanocarrier. Indepen-
dently of modification of the kind of NPs, the viability
Table 2 Characterization of clozapine-loaded nanocarriers
Sample code Mean size [nm] PdI Zeta potential [mV] Clozapine content [mg/l] Concentration [NPs/ml]
CLO-PCL-PEG 87 0.215 − 22 10 4 × 1011
CLO-PCL 99 0.216 − 25 10 3 × 1011
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ofmodel cell was not affected (Kiran et al. 2018; Li et al.
2019; Xie et al. 2018).
CLO-PCL NPs interaction with immune cells
The design of effective nanoformulation of active com-
pound in drug delivery systems requires wide experi-
ments regarding of the interaction between NPs and
immune cells. The nanocarriers should be designed in
the way that enables to avoid opsonin adsorption (the
major process which facilitates recognition and removal
of NPs by phagocytic cells), to increase circulation time
and to allow to achieve the preferred site of action.
Moreover, nanocarriers cannot initiate immune response
processes. Therefore, we performed the set of experi-
ments (NO release, qPCR experiments that allow to
detect the level of major mediators of inflammation) to
characterize pro-inflammatory activity of CLO-PCL
NPs. NO fulfils multiple functions in the body, one of
them is participation in immune response processes. The
obtained results (Fig. 2) clearly show that there was no
significant increase in the level of NO released by the
RAW 264.7 cells, which indicates a possible low
immunogenicity of the synthesized CLO-PCL NPs.
Comparison of the pegylated and non-pegylated CLO-
PCL NPs points to better features of pegylated ones
since slightly lower level of NO was detected.
Moreover, the expression of the following genes:
interleukine 6 (IL-6), tumour necrosis factor (TNF-α),
induced nitric oxide synthase (iNOS) and inhibitory
protein for the factor NF-kB (IĸBα) following incu-
bation of the cells with both types of CLO-PCL NPs
was examined. The reference gene was the gene for
GAPDH (3-phosphoglycerate dehydrogenase) while
the cells incubated without NPs constituted the refer-
ence. Due to the lack of expression of the examined
genes in the reference samples, it was impossible to
determine the Rq value; therefore, the following re-
sults illustrate the cycle number in which the fluores-
cence signal originating from a given gene exceeded
the threshold value. The results shown in Fig. 3
indicate that for both types of CLO-PCL NPs, regard-
less of the used doses, two genes were expressed:
IĸBα and TNF-α. IĸBα protects the cell by binding
with the NF-kB and factor blocking its pro-
inflammatory activity.
Fig. 1 Biocompatibility studies after incubation of cells with both
types (non- and pegylated) CLO-PCL NPs. aMTT assay in HEK
293 cells. bMTTassay in RAW 264.7 cells. c LDH assay in HEK
293 cells. d LDH assay in RAW 264.7 Data are presented as the
means ± standard error (SEM)
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TNF-α is one of the most important cytokines in-
volved in immunological processes, cellular homeostasis
and tumour progression. Its expression may occur inde-
pendently of the incubation with CLO-PCL NPs, as it is
an indispensable factor for the proliferation and proper
functioning of immune cells, including macrophages
(Kulkarni and Feng 2013). This is supported by the fact
that the similar level of TNF-α (to that recorded for
pegylated CLO-PCL NPs) was also observed in the case
of cells that were not incubatedwith CLO-PCLNPs (data
not shown). Comparison of both types of CLO-PCL NPs
shows slight increase in TNF-α expression level induced
by non-pegylated NPs. Moreover, we did not detect IL-6
(one of the cytokines with the strongest pro-
inflammatory effect) expression in case of pegylated
CLO-PCL NPs. Increase of the IL-6 gene expression
level in case of non-pegylated CLO-PCL NPs was ob-
served only for higher doses of NPs (the dose-dependent
effect) but still we can define the dose which was safe and
did not cause expression of that gene (Fig. 3). The most
probably, the undesired immunomodulatory effect de-
tected for unmodified CLO-PCL NPs was connected
with the spontaneous release of clozapine from these
NPs. On the other hand, pegylation of outer surface of
CLO-PCL NPs (besides other features described above)
increased the thickness of the shell which prevented
uncontrolled release of the drug from the particle. It has
been shown recently that CLO stimulates in vivo the
release of cytokines and soluble cytokine receptors
(Pollmächer et al. 2001). This holds true for the tumour
necrosis factor (TNF)-system, the interleukin(IL)-2-sys-
tem, IL-6 and granulocyte colony-stimulating factor (G-
CSF) (Francesconi et al. 2018; Pollmächer et al. 2001).
Moreover, it is likely that TNF-α, IL-6 and other cyto-
kines are involved in metabolic (weight gain, diabetes),
cardiac (myocarditis), CNS (sedation) and other rare side
Fig. 2 NO release from RAW
264.7 cells after 4 h incubation
with both types (non- and
pegylated) CLO-PCL NPs. Data
are presented as the means ±
standard error (SEM)
Fig. 3 qPCR experiments. Expression level of GAPDH, IL-6, TNF-α, iNOS and IκBα determined by Cq. a 4 h incubation with CLO-PCL
NPs. b 4 h incubation with CLO-PCL-PEG NPs. Data are presented as the means ± standard error (SEM)
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effects (Francesconi et al. 2018). Altogether, the obtained
results indicate that pegylated CLO-PCL NPs are safe
CLO nanoformulation, irrespectively of the dose used,
since they do not initiate an immune response in the
RAW 264.7 cells, which is the most important finding
of this part of the study.
Additionally, we determined the ability of both types of
the CLO-PCLNPs tomodulate the phagocytic potential of
the RAW 264.7 cells. The obtained results show a rela-
tionship between the used NPs dose and the efficiency of
the phagocytosis, especially for non-pegylated CLO-PCL
NPs. Moreover, unmodified CLO-PCL NPs showed ten-
dency to reduction of the process (Fig. 4).
It has been shown that CLO reduced the phagocytic
activity of macrophages (Chen et al. 2013). Hence,
probably the observed effect may be connected with
action of clozapine (released from the nanocarrier) and
not the carrier alone. The PEG layer is responsible for
slowing the process of clozapine release from the carrier.
As it was mentioned above, pegylation is one of the
available methods to prevent serum protein adsorption
and non-specific bindings that promote fast NPs uptake.
It is well known that the mechanism of NPs uptake is
cell type specific (Owens and Peppas 2006). Literature
data indicate that the NPs uptake is mediated by a
phagocytic or an endocytic process, but also a passive
mode of uptake was determined (Fond et al. 2013). In
the present studies, flow cytometry technique was
adopted to the kind of experiments. The summary of
obtained data is presented in Fig. 5. The internalization
process was dose dependent. All of synthesized CLO-
PCL NPs were found inside the RAW 264.7 cells;
however, the non-pegylated CLO-PCL NPs were inter-
nalized with increased intensity. Pegylation of the outer
surface of CLO-PCL NPs diminished the process and at
the same time made the nanomaterials more invisible to
the immune cells.
The cellular uptake mechanism was energy-dependent,
what was confirmed by experiments carried out at a lower
temperature (4 °C)—significant inhibition of the process
was recorded. To determine which pathways are engaged
in the endocytosis, the experiments in with specific endo-
cytosis inhibitors added prior to administration of the
CLO-PCL NPs were done. The obtained results indicate
that endocytosis via clathrin-coated vesicles played a key
role in CLO-PCL NPs internalization. The results were
similar to the ones described previously for other polymer-
ic NPs (Łukasiewicz et al. 2015, 2016).
CLO-PCL NPs interaction with in vitro blood-brain
barrier model
The BBB is an active interface between circulation and
the central nervous system (CNS), which restricts the
free movement of different substances between the two
compartments and plays a crucial role in the mainte-
nance of CNS homeostasis (Łukasiewicz et al. 2017).
Recent studies showed the possibility of crossing BBB
by surface modified (by targeting ligand incorporation)
PCL NPs (Xin et al. 2012; Pang et al. 2008; Omarch
et al. 2019). Finding an effective nanocarrier designated
to controlled drug delivery in the brain tissue requires
extensive studies of the interaction of the nanovehicles
with the BBB. The main challenge is the achievements
of brain areas by drug-conjugated NPs. To investigate
the issue, first of all, we should find the most suitable
BBB model which allows to obtain the best outcomes.
Currently, several in vitro models of BBB are available
Fig. 4 Vybrant phagocytosis
assay after 2 h incubation with
both types (non- and pegylated)
CLO-PCL NPs. Data are
presented as the means ± standard
error (SEM)
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(Eigenmann et al. 2013; Weksler et al. 2013); however,
the human hCMEC/D3 cell line which was generated by
immortalizing primary human brain endothelial cells
(Weksler et al. 2013) seems to be the best characterized.
The cells have morphology corresponding to primary
cells, high transendothelial electrical resistance (TEER)
as well as express important BBB proteins engaged in
the formation of tight junction and efflux transporters
[73]. In our laboratory, we have a long-term experience
in working with the above-mentioned cell line; there-
fore, all experiments were performed using this model.
The biocompatibility experiments performed using
Fig. 5 Internalization studies of both types (non- and pegylated)
CLO-PCL NPs by RAW 264.7 cells (flow cytometry analysis). a
Dependence of NPs dose. b, c NPs internalization following
incubation with specific endocytosis inhibitors. Data are presented
as the means ± standard error (SEM)
Fig. 6 Cell viability studies in
hCMEC/D3 cells after 24 h
incubation with both types (non-
and pegylated) CLO-PCL NPs.
Data are presented as the means ±
standard error (SEM)
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CellTiter-Blue assay indicated that synthesized CLO-
PCL NPs did not cause substantial decrease of cell
viability. Although not statistically different, pegylated
CLO-PCL NPs seemed better. Additionally, we did not
observe dose dependence. In Fig. 6, the summary of the
results is presented.
To quantify the CLO-PCL NPs uptake by hCMEC/
D3 cells, the flow cytometry technique was used. Vali-
dation of the method was extremely important since the
experiments should be performed only when the
hCMEC/D3 achieve the proper density level which
enables them to create a BBB model. The preliminary
experiments were done according to previously de-
scribed (Łukasiewicz et al. 2017). When data were
acquired at 4 °C, internalization process was hindered,
but after the temperature raised to 37 °C, the NPs were
uptaken again which suggested that the process was
energy-dependent. Based on obtained results (Fig. 7),
we can say that internalization occurred via endocytosis
mediated by clathrin-coated pits formation.
Moreover, the internalization process was depen-
dent on the used NPs dose. Non-pegylated CLO-
PCL NPs were taken up to the greatest extent. The
difference between both forms of NPs used may
result from the surface charge of the particles.
Pegylated CLO-PCL NPs have twofold lower neg-
ative charge than unmodified ones. It has been
shown that molecules with more negative charge
are more efficiently taken up by BBB model cells
(Kulkarni and Feng 2013). Although pegylated
CLO-PCL NPs were less efficiently internalized
by hCMEC/D3 cells, we can still influence the
process by modifying NPs dose and eventually
achieve desired level of the process.
Fig. 7 Internalization studies of
both types (non- and pegylated)
CLO-PCL NPs by hCMEC/D3
cells (flow cytometry analysis).
Dependence of dose and
internalization following
incubation with specific
endocytosis inhibitors. Data are
presented as the means ± standard
error (SEM)
Fig. 8 Transcytosis studies reflected the feasibility of BBB cross-
ing by both types (non- and pegylated) CLO-PCLNPs in hCMEC/
D3 cells—(transwell pore—3 μm). Similar results were observed
for 1 μm pore size. Y axis—the ratio of positive signal acquired
from basolateral part of transwell insert after incubation of the
hCMEC/D3 cells with coumarin-labelled NPs to signal acquired
from basolateral part of transwell insert characteristic for cells
which were not incubated with NPs
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To achieve brain areas, nanocarriers have to be able
to cross BBB. Because CLO-PCLNPs seem very prom-
ising candidates for CLO delivery, we decided to check
if our nanoformulations could pass through BBB.
Therefore, transcytosis process was investigated. The
surface modification of NPs which determined interac-
tion with cell membrane influences the process. The
study was performed in two different transwell systems
and inserts (1 and 3 μm pore size) and the obtained
results were similar. We observed time dependency.
Moreover, pegylation of CLO-PCL NPs facilitated the
BBB passage in the in vitro model. In Fig. 8, the final
data are presented.
Conclusion
Both obtained CLO-PCL NPs (pegylated and non-
pegylated) have been tested for their possible use as a
novel nanoformulation of CLO. To achieve safe and
efficient targeted therapy using nanoparticulate system,
the wide knowledge of the behaviour of the nanocarrier
in contact with model cells is necessary. The results
obtained in the present study indicate pegylated CLO-
PCL NPs (PEG CLO-PCL NPs) as a promising
nanovehicles. They were not toxic to model cells.
Pegylated outer surface protected from their fast uptake
by macrophages. They were not immunogenic (the im-
munomodulatory effect of clozapine was abolished).
Transcytosis experiments pointed to their ability to cross
a BBB model. The presented experiments were con-
ducted only in the in vitro model but they provide
valuable data in the field of nanotechnology and its
use in novel molecular pharmacology.
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